Skip to content

Cerebrospinal fluid homocysteine, but not plasma homocysteine, is associated with markers of tau pathology and neurodegeneration

Sep 2026 · Journal of Alzheimer's Disease · Vol 113, pp. 1709 - 1716 · 0 citations · 43 references
Medicine

TL;DR

CSF Hcy, rather than plasma Hcy, was associated with markers of tau pathology and neurodegeneration in non-demented older adults, suggesting that CSF Hcy may be more closely associated with tau-related pathological processes during the pre-dementia stages of AD.

Abstract

Background Growing evidence links cardiovascular health to Alzheimer's disease (AD). While elevated plasma homocysteine (Hcy) is associated with cognitive decline, the relationship between cerebrospinal fluid (CSF) Hcy and the core pathological biomarkers of AD remains unclear. Objective This study aimed to investigate the associations of CSF Hcy and plasma Hcy with CSF amyloid-β (Aβ42), phosphorylated tau (p-tau), and total tau (t-tau). Methods A total of 294 non-demented participants (110 cognitively normal, 184 with mild cognitive impairment) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database were analyzed. Multivariate linear regression was used to analyze the relationships between CSF and plasma Hcy levels and CSF Aβ42, phosphorylated tau (p-tau), and total tau (t-tau). Logistic regression analyses assessed the association between Hcy levels and Aβ42 positivity, tau positivity, and neurodegeneration positivity. Results CSF Hcy levels showed significant positive associations with CSF p-tau and t-tau, as well as tau and neurodegeneration positivity. In contrast, no significant association was found between CSF Hcy and Aβ42 pathology. Notably, plasma Hcy was not associated with any AD-related biomarkers. Conclusions CSF Hcy, rather than plasma Hcy, was associated with markers of tau pathology and neurodegeneration in non-demented older adults. These findings suggest that CSF Hcy may be more closely associated with tau-related pathological processes during the pre-dementia stages of AD. Further research is needed to explore the mechanisms underlying these associations.

View source

Similar papers

Open access Aug 2026

CSF p-tau205: a biomarker of Alzheimer's disease progression and biological staging.

CSF p-tau205 as a biomarker of Alzheimer's disease pathology and progression with potential value for biological staging is supported and when incorporated into a conceptual CSF-based staging model, the final p-tau205-positive stage showed the strongest association with cortical atrophy, cognitive impairment, and risk...

J. Lantero-Rodríguez, S. Janelidze, S. Palmqvist et al. · 0 citations
Sep 2026

CSF neuroinflammatory biomarkers are associated with amyloid-β42/40, tau pathology, and cognitive impairment across the Alzheimer’s disease spectrum

Higher CSF neuroinflammatory biomarkers may be linked to AD pathology and cognitive impairment; however, given the observational design, causality cannot be established, and longitudinal mechanistic studies are needed to validate these findings.

Mubarak Alruwaili, A. Turkistani, S. Shilbayeh et al. · 0 citations
Open access Sep 2026

Comparison of amyloid-β, total tau and phospho-tau in clinical AD patients with and without epileptiform EEG patterns.

BACKGROUND Epilepsy is a relevant comorbidity of dementia due to Alzheimer's Disease (AD) and probably directly related to its pathology. We aimed to generate hypotheses how interictal epileptiform discharges (IEDs) may be associated with pathological levels of AD markers from cerebrospinal fluid (CSF). OBJECTIVE To...

Livia Rabea Ott, W. Hermann, Rüdiger Köhling et al. · 0 citations
Open access Sep 2026

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

B. Bellaver, G. Povala, P. C. L. Ferreira et al. · 0 citations
Aug 2026

Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Aβ42 in Alzheimer's Disease.

OBJECTIVE Recent studies suggest that combining plasma phosphorylated tau (p-tau) with β-amyloid (Aβ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross-sectional and longitudinal concordance of these markers with Aβ positron emission tomography (PET) positivity remains incompletely underst...

Mingxing Jiang, Guo-Yu Lan, Jiayi Zhu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.